Marshall Wace’s Ginkgo Bioworks DNA Stock Holding History

Marshall Wace’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$772K	Buy	+77,937	New	+$652K	﹤0.01%	2325
2025 Q2	–	Sell	-263,735	Closed	-$1.5M	–	2808
2025 Q1	$1.5M	Buy	263,735 +196,051	+290%	+$2M	﹤0.01%	1598
2024 Q4	$665K	Buy	+67,684	New	+$580K	﹤0.01%	1924
2024 Q2	–	Sell	-13,612	Closed	-$632K	–	2628
2024 Q1	$632K	Buy	+13,612	New	+$705K	﹤0.01%	1842
2022 Q3	–	Sell	-9,688	Closed	-$924K	–	3425
2022 Q2	$924K	Sell	9,688 -21,880	-69%	-$2.67M	﹤0.01%	2483
2022 Q1	$5.09M	Buy	31,568 +28,862	+1,067%	+$5.62M	0.01%	1352
2021 Q4	$899K	Buy	+2,706	New	+$1.29M	﹤0.01%	2521

Other funds holding DNA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ACG

Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JMFC

J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return

Marshall Wace's DNA Position: Q2 2026 in Review

Marshall Wace opened a new position in Ginkgo Bioworks (DNA) in Q2 2026: 77,937 shares worth $772K. The stake represents ﹤0.01% of the portfolio and ranks #2325 among its holdings. This is a return to the name: Marshall Wace previously reported a position in DNA as recently as Q1 2025.

Marshall Wace first reported a position in DNA in Q4 2021 and has held it in 7 quarters since. The position peaked at $5.09M in Q1 2022. 184 funds tracked by Wall St. Rank hold DNA as of Q2 2026.

Marshall Wace held 77,937 shares of Ginkgo Bioworks worth $772K as of Q2 2026.
Ginkgo Bioworks was a new Marshall Wace position in Q2 2026.
Ginkgo Bioworks made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #2325 holding.
Marshall Wace first reported a position in Ginkgo Bioworks in Q4 2021 and has held it in 7 quarters since.
Marshall Wace's Ginkgo Bioworks position peaked at $5.09M in Q1 2022.
184 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.